New Issue: Orbital Catastrophe Ahead? Read Now

New Ebola Outbreak Declared in the Democratic Republic of the Congo

Experimental therapies, shipped to the DRC for its last outbreak, are still in the country

Health workers operate within an Ebola safety zone near Mbandaka, on June 1, 2018.

Join Our Community of Science Lovers!

A week after the most recent Ebola outbreak in the Democratic Republic of the Congo was declared over, the country has confirmed it has found more cases of the disease.

The new cases are in a province at the opposite end of the country from the earlier outbreak, making it unclear if this is a new epidemic or a continuation of the previous one. But a statement from the ministry of health on Wednesday said the distance of more than 1,500 miles suggests these cases are not linked to the outbreak in Bikoro.

“It’s unlikely to be connected to the previous outbreak,” Jessica Ilunga, a spokeswoman for Health Minister Oly Ilunga, told STAT.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


Samples from four sick people have tested positive for Ebola. But it is still not clear which species of the virus is responsible. There are six known species of ebolaviruses; most outbreaks in DRC have been caused by the Ebola Zaire virus.

The new cases have occurred in North Kivu province, which is located in northeastern DRC, along the border with Uganda and Rwanda. Last weekend the country’s health ministry reported that there had been 26 people sick with fever and “hemorrhagic signs” at a place called Mangina. Of those, 20 had died.

Six samples were sent to the national laboratory in Kinshasa on Tuesday. Testing is still underway to determine the species responsible, Ilunga said.

A team of 12 experts from Kinshasa will arrive in the outbreak area on Thursday to set up the needed components of the response, the health ministry’s statement said. The team will include laboratory technicians, epidemiologists, clinical psychologists, and doctors, and will be equipped with a mobile laboratory and personal protective equipment.

During the Bikoro outbreak, there was grave concern the town’s proximity to the Congo River could allow for spread of the virus to several major cities along the busy waterway, including the DRC capital, Kinshasa.

The geography of this outbreak is different, but also challenging. The region has long been riven with political conflict. North Kivu province is also home to more than 1 million displaced people. And there is significant cross-border travel with Rwanda and Uganda.

“This new cluster is occurring in an environment which is very different from where we were operating in the northwest,” Dr Peter Salama, deputy director-general for emergency preparedness and response at the World Health Organization, said in a statement. “This is an active conflict zone. The major barrier will be safely accessing the affected population.”

The health ministry’s statement noted that experimental Ebola therapies, sent to DRC during the Bikoro outbreak, are still in the country.

“The ethics and scientific committees will determine the most appropriate curative and preventive treatments for this tenth epidemic,” it said.

But determining the species of the virus responsible for the new outbreak will be critical. The experimental vaccine used during the Bikoro outbreak targets Ebola Zaire, as does the ZMapp monoclonal antibody treatment.

If the new cases are caused by a different ebolavirus species, prevention and treatment options will be more limited.

Republished with permission from STAT. This article originally appeared on August 1, 2018

Helen Branswell is STAT's infectious diseases and public health reporter. She comes from the Canadian Press, where she was the medical reporter for the past 15 years. Helen cut her infectious diseases teeth during Toronto's SARS outbreak in 2003 and spent the summer of 2004 embedded at the US Centers for Disease Control and Prevention. In 2010-11 she was a Nieman Global Health Fellow at Harvard, where she focused on polio eradication. Warning: Helen asks lots of questions.

More by Helen Branswell

STAT delivers fast, deep, and tough-minded journalism. We take you inside science labs and hospitals, biotech boardrooms, and political backrooms. We dissect crucial discoveries. We examine controversies and puncture hype. We hold individuals and institutions accountable. We introduce you to the power brokers and personalities who are driving a revolution in human health. These are the stories that matter to us all.

More by STAT

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe